CK Life Sciences Intl (Holdings) Inc → TransCode Therapeutics, Inc. RNAZ

Item 4 of the Original Schedule 13D is hereby amended by adding the below disclosure following the last paragraph: On July 17, 2026, DEFJ submitted an irrevocable conversion notice (the "Conversion Notice") to the Company providing that, contingent upon Company stockholder approval of Proposals 1 and 2 set forth in the Company's proxy statement filed with the SEC on June 2, 2026 for its 2026 annual meeting, DEFJ will, on the third business day following approval of Proposals 1 and 2, convert 21.6755 shares of Series B Preferred Stock into 216,755 shares of Common Stock, such that DEFJ will hold approximately 9.99% of the Company's outstanding Common Stock as of such date.